Skin Care Awareness: Healthy Skin, Healthy Body

Lifestyle Factors: Hydration, Diet, Sleep

Adequate hydration supports skin elasticity and reduces dryness; poor nutrition may lead to cutaneous manifestations such as scurvy or pellagra (PMC, 2015).
Lack of quality sleep worsens inflammatory diseases like eczema and psoriasis, and these conditions in turn degrade sleep quality, creating a vicious cycle (Wiley, 2022; MDPI, 2024).

Sun Protection: Preventing Premature Aging and Cancer

Daily use of broad-spectrum sunscreen (SPF 30+) and protective clothing reduces DNA damage, photoaging (wrinkles, sagging), hyperpigmentation, and significantly lowers the risk of skin cancer—including melanoma (PMC, 2020; Stanford Medicine, 2025).

Conditions Prevented (or Exacerbated) by Poor Skincare

1. Skin Cancer – UV-induced DNA damage; prevented through sun protection and early detection (AIM at Melanoma; EJCancer, 2024).
2. Premature Photoaging – Wrinkles, loss of elasticity, pigmentation from chronic sun exposure and inadequate hydration (Times of India, 2025).
3. Atopic Dermatitis & Eczema – Barrier dysfunction compounded by environmental and lifestyle stressors; improved with physiologic skincare (JDD Online, 2023).
4. Psoriasis – Inflammatory skin disease where supportive barrier care can help reduce flare frequency or severity (Pharmacy Times, 2023).
5. Rosacea – Barrier integrity aids in managing flushing and chronic inflammation (Dermatology Advisor, 2024).
6. Acne – Therapeutic skincare (e.g. salicylic acid, benzoyl peroxide, retinoids) can manage inflammation; gentle routines support barrier health (Wikipedia – Acne).
7. Xerosis in Diabetes – Skin dryness and barrier impairment are prevalent in diabetics; ceramide-based regimens enhance barrier and hydration (JDD Online, 2023).
8. Pressure Ulcers (Bedsores) – Proper cleansing (lukewarm, gentle pH-balanced) and moisturization protect high-friction zones (Cambridge Media, 2022).

Consumer Safety & Role of Dermatologists

Many skincare and cosmetic products still contain allergens or potentially harmful substances (e.g., fragrances, preservatives like parabens, MI/MCI, PEGs), which can induce contact dermatitis or allergic reactions—especially when used chronically or in combinations (“cocktail effect”) (Ann Dermatol, 2010; ResearchGate, 2004).
Survey data also suggest that a significant proportion of consumers experience side effects from skincare products, yet many do not seek dermatologic care, highlighting an opportunity for greater professional guidance (Cureus, 2025).

Conclusion & Call to Action for Dermatology Clinicians

September is officially recognized as Skin Care Awareness Month which is a pivotal opportunity to elevate public understanding that skincare is far more than vanity: it’s fundamental to systemic wellness. This month, take the opportunity to:

• Remind patients that skin health is intertwined with hydration, diet, sleep, and lifestyle habits.
• Emphasize the importance of daily sun protection, barrier-supportive routines (e.g., gentle cleansers, ceramide moisturizers), and early detection of changing skin lesions.
• Educate on choosing safer, evidence-based skincare products, and guide against risky ingredients that may compromise barrier function and trigger inflammation.
• Encourage routine self-exams and annual professional skin evaluations—especially for high-risk individuals.

Dermatology HCPs are uniquely positioned to shift public behavior by championing skincare as the frontline of preventive care and systemic health. Let September be the moment to remind both patients, and perhaps even colleagues, of the foundational power of healthy skin.

Key Strategies to Advance Psoriasis Care

This July, Hyperpigmentation and Melasma Awareness Month reminds us that managing pigmentary disorders requires nuanced clinical judgment, long-term patient support, and culturally aware, competent care. Below are 5 key pillars to help us provide the best possible care for our patients suffering with these conditions.

1. Prioritize Early Diagnosis and Screening

Early recognition and diagnosis, especially of PsA, can prevent long-term damage and disability. The PEST (Psoriasis Epidemiology Screening Tool) is a simple, validated questionnaire used to identify PsA in primary care and dermatology settings [6].
Recommendation: Screen psoriasis patients for joint pain, stiffness, swelling, and fatigue at every visit.

2. Embrace a Multidisciplinary Model

Collaborative care models improve outcomes by addressing both cutaneous and systemic aspects of the disease. Dermatologists, rheumatologists, primary care physicians, cardiologists, mental health professionals, and nutritionists all play a role in care coordination.
• AAD/NPF guidelines support an integrated approach to managing moderate-to-severe disease [7].

Clinical Practice Pearls

✅ Early joint screening prevents irreversible damage
✅ Lifestyle counseling is as critical as pharmacologic therapy
✅ Monitor comorbidities and lab parameters regularly
✅ Communicate with empathy—stigma and isolation are common

Keeping Up with Innovation

Professional development and evidence-based updates are essential for delivering cutting-edge care. Here are several recommended resources:
• National Psoriasis Foundation (NPF) – Guidelines, CME, and tools
• American Academy of Dermatology (AAD) – Clinical practice guidelines
• GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis)

Conclusion: Progress Requires Action

To truly advance psoriasis care, clinicians must shift from reactive to proactive, systemic management. By integrating diagnostics, personalized treatment, and interdisciplinary collaboration, we can reduce disease burden and elevate patient outcomes.

References

1. National Psoriasis Foundation. Psoriasis Statistics. https://www.psoriasis.org
   2. Mease PJ, et al. “Prevalence of Psoriatic Arthritis in Patients With Psoriasis.” J Am Acad Dermatol. 2013;69(5):729–735.
   3. Takeshita J, et al. “Psoriasis and comorbid diseases: Epidemiology.” J Am Acad Dermatol. 2017;76(3):377–390.
   4. Gelfand JM, et al. “Risk of myocardial infarction in patients with psoriasis.” JAMA. 2006;296(14):1735–1741.
   5. Kurd SK, Gelfand JM. “The prevalence of previously diagnosed and undiagnosed psoriasis in US adults.” J Am Acad Dermatol. 2009;60(2):218–224.
   6. Ibrahim GH, et al. “Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new tool: the PEST questionnaire.” Br J Dermatol. 2009;161(3):474–480.
   7. Elmets CA, et al. “Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.” J Am Acad Dermatol. 2019;80(4):1029–1072.
   8. Reich K, et al. “Secukinumab induction and maintenance therapy in moderate-to-severe psoriasis.” Lancet. 2015;386(9993):1311–1320.
   9. Gordon KB, et al. “Efficacy and safety of guselkumab in moderate-to-severe psoriasis: Results from VOYAGE 1 and 2.” Lancet. 2017;389(10066):2287–2301.
   10. Fleming P, et al. “The prevalence of anxiety in patients with psoriasis: A systematic review and meta-analysis.” J Eur Acad Dermatol Venereol. 2017;31(5):798–807.
   11. Armstrong AW, et al. “Obesity and severity of psoriasis: a systematic review and meta-analysis.” J Invest Dermatol. 2012;132(9):2196–2203.

#PsoriasisCare #PsoriaticDisease #Dermatology #Rheumatology #InflammatoryDisease
#ChronicDiseaseManagement #PsoriaticArthritis #BiologicTherapy #HealthcareLeadership #ClinicalEducation#InterdisciplinaryCare #PatientCenteredCare #AutoimmuneDisease #MentalHealthInChronicIllness #EvidenceBasedMedicine